You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Compound E
Compound E is a γ-secretase and notch patchway inhibitor. Compound E enhances growth inhibition, differentiation and migration of neuroblastoma cells when used in a combination with DAPT (Cat. No. 2634) and 13-cis RA. In combination with hLIF, CHIR 99021 (Cat. No. 4423) and SB 431542 (Cat. No. 1614), Compound E accelerates the induction of a homogeneous, self-renewing primitive neuroepithelium population from hESCs. Compound E is active in vitro and in vivo.
For more information about how Compound E may be used, see our protocol: Generation of β cells from hPSCs
Technical Data for Compound E
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Compound E
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Compound E
The following data is based on the product molecular weight 490.5. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.04 mL||10.19 mL||20.39 mL|
|5 mM||0.41 mL||2.04 mL||4.08 mL|
|10 mM||0.2 mL||1.02 mL||2.04 mL|
|50 mM||0.04 mL||0.2 mL||0.41 mL|
References for Compound E
References are publications that support the biological activity of the product.
Li et al (2011) Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc.Natl.Acad.Sci.USA 108 8299 PMID: 21525408
Ferrari-Toninelli et al (2010) Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro.Oncol. 12 1231 PMID: 20716592
Beher et al (2001) Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology. J.Biol.Chem. 276 45394 PMID: 11574530
If you know of a relevant reference for Compound E, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Compound E, Compound E supplier, gamma-secretase, g-secretase, inhibitors, XXI, inhibits, secretases, neuronal, differentiation, neurons, self, renewal, notch, pathway, Gamma, Secretase, Inhibitor, Gamma-Secretase, Neural, Stem, Cells, Organoids, 6476, Tocris Bioscience
2 Citations for Compound E
Citations are publications that use Tocris products. Selected citations for Compound E include:
Zhan et al (2022) Pancreatic islet cryopreservation by vitrification achieves high viability, function, recovery and clinical scalability for transplantation. Nat.Med. 28 798 PMID: 35288694
Sheng et al (2018) A stably self-renewing adult blood-derived induced neural stem cell exhibiting patternability and epigenetic rejuvenation. Nat Commun 9 4047 PMID: 30279449
Do you know of a great paper that uses Compound E from Tocris? Please let us know.
Reviews for Compound E
There are currently no reviews for this product. Be the first to review Compound E and earn rewards!
Have you used Compound E?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Protocols for Compound E
The following protocol features additional information for the use of Compound E (Cat. No. 6476).
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.